RASSF tumor suppressor gene family: Biological functions and regulation

Natalia Volodko a, Marilyn Gordon a, Mohamed Salla b, Haya Abu Ghazaleh d, Shairaz Baksh a,b,c,* 1

a Department of Pediatrics, Faculty of Medicine and Dentistry, 113 St. 87 Ave., University of Alberta, Edmonton, AB T6G 2E1, Canada
b Department of Biochemistry, Faculty of Medicine and Dentistry, 113 St. 87 Ave., University of Alberta, Edmonton, AB T6G 2E1, Canada
c Department of Oncology, Faculty of Medicine and Dentistry, 113 St. 87 Ave., University of Alberta, Edmonton, AB T6G 2E1, Canada
d The American University of the Middle East, P.O. Box: 220 Dasman, 15453, Kuwait

A R T I C L E I N F O

Article info
Received 17 January 2014
Revised 25 February 2014
Accepted 25 February 2014
Available online xxxx
Edited by Shairaz Baksh, Giovanni Blandino and Wilhelm Just

Keywords:
RASSF
Cancer
Epigenetics
Tumor suppressor
Microtubule
NFκB

A B S T R A C T

Genetic changes through allelic loss and nucleic acid or protein modifications are the main contributors to loss of function of tumor suppressor proteins. In particular, epigenetic silencing of genes by promoter hypermethylation is associated with increased tumor severity and poor survival. The RASSF (Ras association domain family) family of proteins consists of 10 members, many of which are tumor suppressor proteins that undergo loss of expression through promoter methylation in numerous types of cancers such as leukemia, melanoma, breast, prostate, neck, lung, brain, colorectal and kidney cancers. In addition to their tumor suppressor function, RASSF proteins act as scaffolding agents in microtubule stability, regulate mitotic cell division, modulate apoptosis, control cell migration and cell adhesion, and modulate NFκB activity and the duration of inflammation. The ubiquitous functions of these proteins highlight their importance in numerous physiological pathways. In this review, we will focus on the biological roles of the RASSF family members and their regulation.

© 2014 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.

1. Introduction

The RASSF family of proteins is comprised of ten members each with multiple splice variants, with the exception of RASSF9 and 10 [1,2]. These proteins were named due to the presence of a Ras association (RA) domain in their N-terminus or C-terminus. The RA domain potentially interacts with the Ras GTPase family of proteins [2] that control a number of cellular processes including membrane trafficking, apoptosis, and proliferation [1–5]. Direct association with K-Ras has been only observed for RASSF2, 4, 5A, 6 and 9 [6–8]. In addition, RASSF proteins have several other functional domains that modulate associations with other proteins (see Table 1 for the list of RASSF interacting partners). These include a Salvador-RASSF-Hippo (SARAH) domain involved in several protein–protein interactions and for homo- and heterodimerization of RASSF isoforms. RASSFs can associate via the SARAH domain with downstream kinases such as mammalian sterile 20-like kinases (MST1 and MST2 [mammalian Hippo] also known as STK4 and STK3 respectively) and the mammalian orthologue of the tumor suppressor Salvador, SAV1 in order to promote apoptosis [9]. These various structural domains allow for associations with numerous molecules and determine RASSF proteins’ involvement in several biological pathways in order to carry out tumor suppressor functions.

An ATM phosphorylation site is present on some RASSF proteins (RASSF1A and RASSF1C), and RASSF1A and RASSF1C also contain an N-terminal protein kinase C conserved region 1 (C1) domain that co-localizes with microtubules [1]. The C1 domain has also been demonstrated to allow for the association of RASSF1A with death receptor complexes, such as TNF-R1 and TRAIL [10]. The ATM phosphorylation site has been found to be phosphorylated in several RASSF proteins upon DNA damage/repair [11] (Reviewed in [12]).

2. The diverse nature and biological function of RASSF proteins

2.1. RASSF1A

In 2000 Dammann et al. cloned a gene that was mapped to the 3p21.3 region, whose genomic instability was frequently described in lung cancer. The gene was named RASSF1 as it contains Ras-association domain [13]. RASSF1 has eight transcripts (A–H),
Table 1
Summary of currently known biological information of the RASSF family of proteins.

<table>
<thead>
<tr>
<th>RASSF isoform</th>
<th>Chromosome/MW</th>
<th>Biological functions</th>
<th>Interacting proteins</th>
<th>Mouse knockout</th>
</tr>
</thead>
<tbody>
<tr>
<td>4 10q11.21 36.7 kDa</td>
<td>Required for apoptosis and growth inhibition [8] Inhibits MST2 activity [93] Modulates the MAP kinase signal downstream of the Ras signal [77]</td>
<td>MST1 [43,177] MST2 [177]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5C (Nore1B, RAPL) 1q32 30.4 kDa</td>
<td>Regulates lymphocyte adhesion, T cell migration, T cell receptor regulation [84,86,186] Controls the directional migration of vascular endothelial cells [6]</td>
<td>MST1 [93] K-Ras, MOAP-1 [87] MST1, MST2 [177] MDM2 [94]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8 12p12 48.3 kDa</td>
<td>Inhibits cell growth, regulates Wnt and NFκB pathways, regulates cell-cell adhesion [4]</td>
<td>Peptidylglycine α-amidating monoxygenase [111] N-, K- and R-Ras [188] [contradicts to [177]] Not available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9 12q21.31 50.0 kDa</td>
<td>Possible role in endosome recycling [110] Essential for epidermal homeostasis [112]</td>
<td>Peptidylglycine α-amidating monoxygenase [111] N-, K- and R-Ras [188] [contradicts to [177]] Not available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10 11p15 56.9 kDa</td>
<td>Suppresses tumor cell growth [189,190]</td>
<td>MST1, MST2 [177] MDM2 [94]</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The table summarizes current knowledge of the RASSFs with their chromosomal location, protein molecular weights (MW), biological functions, association partners and genetic knockouts.
It was shown that loss of RASSF1A in Apc aberrant Wnt pathway signaling and adenoma initiation [37,38]. Among the RASSF1 subtypes, 1A and 1C are the most extensively studied members with both localized to microtubules and involved in regulation of growth and migration [14,15]. Whereas RASSF1C may promote the proliferative capacity of cancer cells (especially breast and lung cancer cells) [16–18], RASSF1A is a bona fide tumor suppressor [1,2]. Thus, despite harboring 60% amino acid identity (mainly after amino acid 121 of RASSF1A), RASSF1A and RASSF1C display distinctive biological properties.

Several groups have demonstrated the importance of RASSF1A for microtubule stability and have mapped residues important for this function [10,14,19–21]. RASSF1A interacts with microtubules though interaction with microtubule associated proteins, such as MAP1B (microtubule-associated protein 1B) and MAP1S (microtubule-associated protein 1S) [14]. The loss of RASSF1A microtubule localization results in the inhibition of tumor suppressor properties, loss of tubulin stability, inhibition of death receptor-dependent cell death and promotion of genomic instability through the loss of centrosome and mitotic spindle body structures [14,19,20]. One of the possible mechanisms of microtubule stabilization by RASSF1A involves RAN GTPase [22], and another mechanism discovered recently includes the suppression of histone deacetylase 6 which functions as a tubulin deacetylase [23]. The ability of RASSF1A to regulate microtubule stability, spindle assembly and chromosome attachment determine RASSF1A tumor suppressor functions towards controlling cell growth, transformation, motility and invasiveness [15,19,24].

Further studies have shown that interaction of RASSF1A with RABP1 (RASSF1A binding protein 1/C19ORF5/MAP1S) leads to its recruitment to the spindle poles in pro-metaphase and its interaction with Cdc20 [25] (please note that there is a contradictory report on RASSF1A interaction with Cdc20 [26]), inhibition of APC (anaphase promoting complex), accumulation of mitotic cyclins A and B and eventually mitotic arrest [25,27,28]. Upon phosphorylation by Aurora A, RASSF1A fails to interact with Cdc20 thereby relieving APC inhibition, leading to degradation of cyclins and mitotic progression [29]. Interestingly, RABP1/MAP1S was recently shown to enhance autophagy by suppressing genomic instability and tumorigenesis [30]. Furthermore, it has also been suggested that RASSF1A stabilization of microtubules may have a role in autophagy regulation [30].

Along with mitotic progression, RASSF1A was shown to regulate other aspects of the cell cycle. RASSF1A inhibits accumulation of cyclin D1 (possibly through JNK kinase pathway [31,32], suppression of AP-1 activity [27], or both) and blocks the cell cycle at the G1/S-phase [31,32]. RASSF1A was also shown to associate with and increase the activity of p120catenin, a transcription factor known to bind the cyclin A2 promoter [33,34] and p21Cip1/Waf1 cyclin-dependent kinase inhibitor [35]. Another mechanism by which RASSF1A controls cell cycle and apoptosis is by the disruption of the MDM2–DAXX–HAUSP complex leading to MDM2 self-ubiquitination and stabilization of p53 [36].

The role of RASSF1A in β-catenin signaling pathway was shown using ApccMin mice, a model of intestinal tumorigenesis. Mutations of the adenomatous polyposis coli (APC) gene are a frequent and early event in colorectal cancers. APC inactivation leads to reduced β-catenin degradation and its nuclear accumulation, thus causing aberrant Wnt pathway signaling and adenoma initiation [37,38]. It was shown that loss of RASSF1A in ApccMin mice resulted in a significant increase in adenomas of the small intestine and accelerated intestinal tumorigenesis [39]. Immunohistochemical analysis revealed increased nuclear accumulation of β-catenin in Rassf1a−/−; ApccMin mice, supporting a mechanistic link via loss of the known interaction of RASSF1A with β-TrCP that mediates degradation of β-catenin [39].

We have demonstrated the importance of RASSF1A in death receptor dependent cell death via associations with TNF-R1, TRAIL-R1 and modulator of apoptosis (MOAP-1) [40,41]. In addition, RASSF1A can also associate with the pro-apoptotic kinase, MSt1/2 to modulate its kinase activity and promote cell death [9,42–45]. These associations function to prevent excessive growth and allow RASSF1A to function as a tumor suppressor. We also recently demonstrated that, under conditions of acute intestinal inflammation, RASSF1A restricts NFκB activity by interfering with the ability of the membrane proximal TLR/MyD88/TRAF6/IRAK2/4 complex to promote downstream signaling to NFκB [46]. The restriction of NFκB activity also led to restriction of tyrosine (Y) 357 phosphorylation of Yes associated protein (YAP), a key Hippo-dependent transcription factor linked to proliferation [46]. We determined that Y357 phosphorylation of YAP may arise due to increased inflammation and DNA damage – both of which are prominent during intestinal inflammation injury stimulated by the colonic irritant, dextran sodium sulfate (DSS) [46]. We are currently exploring the molecular mechanisms modulating the Y357 phosphorylation of YAP and of its importance for the appearance and/or progression of inflammatory bowel disease.

Rassf1a−/− mice (on the C57BL/6 background) are viable, fertile and retain expression of isoform 1C and other RASSF gene family members. They have an increased tumor incidence by 12–16 months of age (especially in the breast, lung, gastrointestinal (GI) and immune system [B-cell related lymphomas]) and develop tumors in response to chemical carcinogens [47,48]. When Rassf1a−/− mice were subjected to cardiac stress by pressure overload they responded with an exaggerated hypertrophic response with the formation of enlarged cardiac myocytes and hearts. Forced expression of RASSF1A in rat neonatal cardiac myocytes suppressed Raf-1 and ERK1/2 activation and inhibition of phosphoryl-ephrine-induced cardiac myocyte growth [49]. Rassf1a−/− mice revealed surprising cell specificity of RASSF1A signaling in the heart with cardiomyocytes and fibroblasts showing different signaling responses. In cardiomyocytes RASSF1A primarily induced apoptosis and inhibited hypertrophic cell growth. In cardiac fibroblasts, however, RASSF1A repressed NFκB activity and inhibited TNFα secretion, preventing paracrine hypertrophic signaling between fibroblasts and myocytes [50]. For more detailed discussion of RASSF1A regulatory mechanisms in the heart please see recent review by Duan et al. [51].

Recently, we showed that Rassf1a−/− mice are susceptible to DSS-induced colitis [46]. Rassf1a−/− mice displayed clinical symptoms of inflammatory bowel disease (IBD) including increased intestinal permeability, enhanced cytokine/chemokine production, elevated NFκB activity and elevated colonic cell death and epithelial cell injury [46]. Aged Rassf1a-null mice have an enhanced susceptibility to spontaneous inflammation at >6 months of age (S. Baksh, unpublished observations) and megaesophagus [52]. Histological examination revealed chronic inflammatory infiltrate and subsequent fibrosis of the myenteric plexus and the muscle layers [52]. These studies support a role of RASSF1A in modulating NFκB activity and in restricting uncontrolled inflammation leading to several disease states.

2.2. RASSF1C

As mentioned earlier, in contrast to RASSF1A, RASSF1C does not have tumor suppressor properties with increasing evidence suggesting that it functions as an oncogene. Overexpression of RASSF1C in breast cancer cells resulted in enhanced cell migration/invasion [17]. It was also reported that RASSF1C could activate osteoblast cell proliferation through interaction with IGFBP-5 [18]. It was shown recently that RASSF1C is a very unstable protein...
regulated by polyubiquitylation by the Mule E3 ligase under normal conditions. Upon DNA damage Mule as well as SFCβ-TrCPα are involved in the RASSF1C degradation [53]. The association of RASSF1C with SFCβ-TrCPα ligase was also described previously in a study whereby the authors showed that β-catenin accumulation was promoted either by the overexpression of RASSF1C (which inhibited β-catenin degradation) or by the silencing of RASSF1A, implying that the balance between the two isoforms is crucial for the βTrCP-mediated degradation of β-catenin [5].

RASSF1C has been shown to form a complex with DAXX and localize to promyelocytic leukemia-nuclear bodies in the nucleus. Upon DNA damage DAXX is degraded and RASSF1C is released into the cytoplasm where it activates the SAPK/JNK pathway [54]. Using yeast two-hybrid system, Chen et al. found that RASSF1C may also interact and co-localize in the nucleus with tissue factor pathway inhibitor-2 (TFPI-2), a serine-proteinase inhibitor implicated in inflammation, angiogenesis and tumor growth/metastasis, suggesting other potential roles for RASSF1C [56]. To date, no known Rassf1c knockout mouse has been established.

2.3. RASSF2

The RASSF2 gene is transcribed into two major isoforms (A and C) that lack the C1 and ATM domains present in RASSF1A (Reviewed in [2]). It is primarily a nuclear protein unlike RASSF1A and 1C [57]. Promoter methylation and loss of expression of RASSF2 has been reported in different cancers and cancer cell lines [58–61] implicating the correlation and significance of RASSF2 in tumorigenesis. In addition, transient expression of RASSF2 in 293T embryonic kidney cells showed prominent growth inhibition enhanced by activated K-Ras [62]. Furthermore, in situ staining and fluorescent microscopy illustrated that the attenuation of cell growth in RASSF2 expression systems was the resultant effect of apoptosis [62]. Regulation of cell growth by RASSF2 was reported in situ. Expression of PAX3 in a pituitary somatotroph adenoma [69]. RASSF3 expression via the ERK pathway [79]. In addition, RASSF5A can inhibit cell proliferation independently of MST1/2 kinases [80]. It was also demonstrated that RASSF4 interacted with and inhibited the tumor suppressor MST1/1Hippo, suggesting that RASSF4 may act as a Hippo pathway inhibitor. A further study revealed suppressed Hippo signaling in aRMS, that was reflected in high expression level of YAP (Yes-associated protein 1). Although attempts to find a clear cause and effect relationship between YAP and RASSF4 biology failed, YAP was shown clearly to be involved in senescence regulation [75]. Interestingly, earlier studies have shown that RASSF4 associated directly with activated K-Ras and induced cell death in 293T embryonic kidney and MCF-7 breast cancer cells [8], indicating a tumor suppressor role of RASSF4. However, the human lung tumor cell line H1299 was completely resistant to RASSF4-mediated growth inhibition, suggesting cell line dependence of RASSF4 functions [8]. It will be interesting to explore what determines the pro- or anti-tumor functions of RASSF4. One of the proposed regulators might be p53 [8], since H1299 cells (but not MCF-7 cells) are defective for p53. It was also suggested that RASSF4 may suppress the MAP kinase signal by suppression of ERK phosphorylation [77] thus providing another possible mechanism for RASSF4-mediated tumor suppression. To date, no known RASSF4 knockout has been generated.

2.5. RASSF4

RASSF4 has 25% and 60% identity with RASSF1A and RASSF2 respectively [8]. Current studies demonstrate that RASSF4 is broadly expressed in normal tissues [8,73,74] and the reduction of RASSF4 expression due to promoter specific hypermethylation was detected in tumor cell lines and primary tumors [8,73,74] suggesting that RASSF4 might act as a tumor suppressor. However, a recent paper revealed a pro-growth role for RASSF4 in alveolar rhabdomyosarcoma (aRMS) [75]. One of the subtypes of aRMS is characterized by paired box-3-forkhead box protein O1 (PAX3-FOXO1) – a chimeric protein, arising as a result of chromosomal translocation. The expression of PAX3-FOXO1 is associated with an 8% survival of patients past 4 year [76]. Using cell free models it was demonstrated that PAX3-FOXO1 transcriptionally upregulates RASSF4 which in turn inhibits cellular senescence and promotes cell proliferation [75]. It was also demonstrated that RASSF4 interacted with and inhibited the tumor suppressor MST1/Hippo, suggesting that RASSF4 may act as a Hippo pathway inhibitor. A further study revealed suppressed Hippo signaling in aRMS, that was reflected in high expression level of YAP (Yes-associated protein 1). Although attempts to find a clear cause and effect relationship between YAP and RASSF4 biology failed, YAP was shown clearly to be involved in senescence regulation [75]. Interestingly, earlier studies have shown that RASSF4 associated directly with activated K-Ras and induced cell death in 293T embryonic kidney and MCF-7 breast cancer cells [8], indicating a tumor suppressor role of RASSF4. However, the human lung tumor cell line H1299 was completely resistant to RASSF4-mediated growth inhibition, suggesting cell line dependence of RASSF4 functions [8]. It will be interesting to explore what determines the pro- or anti-tumor functions of RASSF4. One of the proposed regulators might be p53 [8], since H1299 cells (but not MCF-7 cells) are defective for p53. It was also suggested that RASSF4 may suppress the MAP kinase signal by suppression of ERK phosphorylation [77] thus providing another possible mechanism for RASSF4-mediated tumor suppression. To date, no known RASSF4 knockout has been generated.

2.6. RASSF5

RASSF5 (also called NORE1 or RAPL) was the first member of RASSF proteins to be cloned [78]. It is expressed as three transcripts (A–C) via differential promoter usage and alternative splicing. The longest form of RASSF5A has 40% amino acid similarity with RASSF1A. RASSF5A has been shown to associate with cytoskeletal proteins through its RA domain and promote growth suppression via the ERK pathway [79]. In addition, RASSF5A can complex with MST1 kinase upon TNF-α and TNF-related apopto-

Please cite this article in press as: Volodko, N., et al. RASSF tumor suppressor gene family: Biological functions and regulation. FEBS Lett. (2014), http://dx.doi.org/10.1016/j.febslet.2014.02.041
diversity of effectors through which RASSF5 exerts its proapoptotic role suggests that apoptosis control is a very important function of RASSF5.

The C57BL/6-Rassf5a−/− mice were just recently generated but do not have an overt phenotype nor evidence of tumor formation as they age [80]. However, cells from the Rassf5a−/− mice were resistant to TNFα and TRAIL-dependent cell death and reduced activation of JNK kinases in response to TNFR stimulation failed to activate MST1 in vivo [80]. In line with the role of RASSF5 as a tumor suppressor, K-Ras transfectant mouse embryonic fibroblasts developed a significant amount of tumors when injected into immune compromised mice to support the role of RASSF5 in restricting excessive growth [80]. Recently it was demonstrated that Rassf5a plays a role in developing the nervous system [83].

The shortest RASSF5 isoform RASSF5C/NORE1b/RAPL is expressed predominantly in lymphoid tissues [84] and was shown to act as a mediator of the Rap1 induction of integrin clustering and activation after T-cell receptor stimulation [84], hence it was named as RAPL (regulator for cell adhesion and polarization enriched in lymphoid tissues). Whereas most functional studies were focused on RASSF5A, there is direct evidence that RASSF5C can suppress growth and colony formation in cells to the same extent as RASSF1A (although not in all cell lines tested) [82].

It was shown that RAPL is important for p27 (a regulator of cell cycle progression) nuclear localization in lymphocytes upon antigen receptor stimulation. RAPL deficiency resulted in the cytoplasmic localization of p27 and hyperproliferation of both T and B cells. Rapl-deficient mice developed lupus-like autoimmunity and B cell lymphomas, suggesting that the regulation of p27 under cellular localization by RAPL serves as a checkpoint for S phase entry to prevent immunoproliferative disorders [85]. Mice deficient in RASSF5C exhibited impaired lymphocyte trafficking and lymphoid organ abnormalities [86].

2.7. RASSF6

A few years following the discovery of RASSF1, a new Ras effector protein, RASSF6 showing similar structural topography to that of other RASSF proteins, was characterized and mapped [87,88]. To date, three isoforms of RASSF6 (A–C) have been identified [reviewed by [89]]. Similar to other RASSFs, RASSF6 behaves like a tumor suppressor protein and is epigenetically silenced in childhood leukaemias and neuroblastomas [90,91]. Overexpression of RASSF6 in Hela cells induced apoptosis via a signaling mechanism that is associated with Bax activation and cytochrome c release [92]. Furthermore, RASSF6 and MST2 inhibited each other under basal conditions but dissociated upon stimulation resulting in apoptosis in a RASSF6-WW45-dependent manner. However, the authors also demonstrated that RASSF6 was able to induce apoptosis in a parallel WW45-independent manner. RASSF6 association with MST2 inhibits canonical Hippo pathway activation [93]. Interestingly, it was demonstrated that RASSF6 binds to MDM2 and facilitates its self ubiquitination and degradation, stabilizing p53 (like RASSF1A and RASSF3), thereby regulating apoptosis and cell cycle [94]. It also has been demonstrated that, similar to RASSF1A and RASSF2, RASSF6 can inhibit Nfkb activity and possibly inflammation by unknown mechanisms [87]. To date, no known Rassf6 knockout mouse has been generated.

2.8. RASSF7

In 1994 Weitzel and Patel identified an aggregate of genes on chromosome 11p15, surrounding Hras1 cluster 1 [95]. The upstream gene was originally named Hrc1 (HRAS1-related cluster protein 1) and was later renamed as RASSF7. Due to alternative splicing, RASSF7 is comprised of three transcripts (A–C) containing an N-terminal RA domain but lacking the SARAH domain conserved among RASSF1–6 family members [89]. RASSF7 is ubiquitously expressed in many tissues, specifically in brain, lung, and human cell lines and is up regulated in several carcinomas such as islet cell tumors [96], pancreatic ductal carcinoma [97–99], endometrial cancer [100] and ovarian clear cell carcinomas [101]. Protein and mRNA expression of RASSF7 was shown to be enhanced upon hypoxic insults [102] which, given the hypoxic nature of solid tumours, might explain the increase in RASSF7 expression seen in tumor cells. No promoter methylation of the RASSF7 gene was found in 57 cancer cell lines in the study by Recino et al. [102]. Conversely, Djos et al. reported that Cpg island of the RASSF7 gene was heavily methylated in neuroblastoma cell lines suggesting that RASSF7 might be involved in the regulation of tumor formation [90]. Functional analyses demonstrated that RASSF7 induces cell growth through the regulation of spindle formation subsequently promoting mitotic progression [102,103]. A recent study illustrated the role of RASSF7 in cell survival during periods of stress. During initial stress, RASSF7 associates with N-Ras, inhibiting MK7/JNK signaling pathway and inducing cell growth [104]. However, the anti-apoptotic property of RASSF7 is soon lost following prolonged exposure of UV radiation, due to degradation of RASSF7 through ubiquitination [104]. Thus, the mounting evidence so far argues a tumor suppressor function for this RASSF protein. Currently, no known Rassf7 knockout has been generated.

2.9. RASSF8

Seven transcripts of RASSF8 have been identified so far [89]. Similarly to RASSF7, RASSF8 isoforms contain an N-terminal RA domain and lacks the SARAH region [89]. The tumor suppressor role of RASSF8 was initially proposed due to reduced transcript levels of RASSF8 in lung adenocarcinomas [105]. Loss of RASSF8 does not appear to be due to promoter methylation, except possibly in childhood leukemia [91] and the mechanism for RASSF8 down-regulation in many cancers remains to be elucidated. Further studies demonstrated that transient expression of RASSF8 in lung carcinoma cells attenuated cell growth in soft agar [105]. Collectively, these findings support the notion that RASSF8 regulates tumor development. Additional functions of RASSF8 include cell–cell adhesion due to its association with adherens junction linked to β-catenin/E-cadherin function [4]. Wound healing assays exhibited increased cell migration in cells lacking RASSF8 expression, suggesting that loss of RASSF8 may contribute to tumor aggressiveness [4]. However, serum analysis indicated that mRNA levels of RASSF8 in blood plasma were elevated in breast cancer patients in comparison to healthy controls [106], suggesting a tumor promoter effect of RASSF8. Early studies demonstrated that RASSF8 interacts with the adapter protein 14-3-3 [107], an ubiquitously expressed scaffolding protein that regulates various molecular processes including apoptosis and cell cycle progression [108]. Interestingly, RASSF1A-mediated cell death can be regulated by 14-3-3 as well [109]. Thus, these adapter proteins appear to be pivotal in the functional regulation of RASSF proteins. To date, no known Rassf8 knockout has been generated.

2.10. RASSF9

RASSF9 was previously known as P-CIP1, peptidylglycine α-amidating monooxygenase COOH-terminal interactor protein-1 and regulates the distribution and ultimate fate of peptidylglycine alpha-amidating monooxygenase in endosomal pathways [110,111]. However, following BLAST analysis, P-CIP1 revealed similar structural homology to RASSF7 and RASSF8 and was later named RASSF9 [3]. RASSF9 contains the conserved RA domain localized at the C-terminus similarly to RASSF7, 8 and 10 [3]. Little
is known about the expression and functional significance of RASSF9. In 2011, Chang’s group reported the predominant expression of RASSF9 in epithelial tissue [112]. Rassf9-deficient mice exhibited signs of senescence including increased alopecia, shorter life expectancy and growth retardation, implicating its role in epidermal development [112].

2.11. RASSF10

RASSF10 shares similar structural features to that of RASSF7–9, whereby it comprises an N-terminal RA domain and lacks the SARAH region [91]. RASSF10 was shown to be expressed in bone marrow as well as thyroid, brain, prostate and kidney [91,113–115]. Concomitantly, hypermethylation of RASSF10 was associated with loss of gene and protein expression in cancer conditions such as childhood leukemias, thyroid carcinomas and gliomas [91,113,114]. The transcription of RASSF10 was restored using a demethylating agent [116]. In vitro analyses in U87 glioma cells treated with RNAi to knockdown RASSF10 expression, showed increased cell proliferation and cell survival [113]. Re-expression of RASSF10 in these cells inhibited cell growth and colony formation of glioma cells highlighting the tumor suppressor function of RASSF10 [113]. More recently, the tumor suppressor activity of RASSF10 was assessed in gastric cancer cells, demonstrating that reintroduction of RASSF10 in gastric cell lines JRST and BGC823 reduced cell viability and promoted apoptosis [116]. The pro-apoptotic nature of RASSF10 was shown to involve the Wnt/β-catenin signaling pathway [116]. Additionally, RASSF10 may play a potential role in the regulation of mitotic progression due to its localization to centrosomes and microtubule association [113]. In light of the existing information, it appears that RASSF10 is a strong candidate as a prognostic marker to screen certain carcinomas.

3. Epigenetic regulation of the RASSFs

Epigenetics has now emerged as a key driver of disease states such as cardiovascular diseases, cancer, and schizophrenia. It is a mechanism that results in the changes of gene expression without an underlying change in the nucleotide sequence or in the ability of the organism to transfer the change to the next generation. Although epigenetic changes are not directly transferred to the next generation, in most cases the susceptibility for change to occur in a specific region is transferred and thus can have familial links.

Epigenetic changes can be in the form of histone modification leading to chromatin remodeling or by the conversion of cytosine to 5-methylcytosine. The latter occurs on specific CG-rich DNA stretches termed “CpG islands” within the promoter region and interferes with normal transcription [117,118]. DNA methylation is maintained by DNA methyltransferase 1 (DNMT1), which predominantly methylates hemi-methylated DNA. DNMT3a and DNMT3b methyltransferases are responsible for de novo methylation of unmethylated CpG. Although methylation is a drastic change, it can be reversed with the use of 5-Aza-2′-deoxycytidine (a cytidine analog that inhibits DNA methylation) [119]. However, the use of 5-Aza-2′-deoxycytidine has its limitations and targeted delivery to the affected area has posed challenges for its use as a potential therapeutic agent.

As mentioned before, several RASSF family members are regulated by promoter specific epigenetic changes. RASSF1A was the first to be identified and is considered to be one of the most methylated genes in human cancer. Not only is it epigenetically silenced in numerous cancers but it is considered as one of the earliest detectable changes in cancer [120]. Reports show that epigenetic silencing of RASSF1A occurs at a prevalence of 10–30% in cervical cancer, 60% in breast cancers to 80% in small cell lung cancer and up to 99% in prostate cancer (see Table 3 for the complete list and references). Epigenetic modifications occur on >60 CpG sites spanning the RASSF1A promoter and exon 1. Silencing can be detected in numerous cell lines and can be reversed using 5-aza-2′-deoxycytidine, machanine [76], curcumin [121] or the approved FDA drug for treating acute myeloid leukemia, decitabine.

The correlation of RASSF1A methylation with different tumor characteristics has been reported by several groups. RASSF1A promoter methylation correlated inversely with K-Ras and B-Raf mutation status in cervical adenocarcinomas [122] and thyroid cancers [123–125]. RASSF1A methylation was also shown recently to inversely correlate with TP53 mutations [120], suggesting that they likely have independent mechanisms in tumourigenesis. A positive correlation between the degree of RASSF1A methylation and higher tumor grade [51,120], the ability of deeper myometrial invasion and positive metastatic involvement of pelvic lymph nodes in endometrial cancer was reported [51]. Interestingly, RASS-F1A hypermethylation correlated with chromosome instability in Wilms’ tumors [126] supporting a role for RASS1A in controlling genomic stability. Subtype-specific difference in methylation was described in lung cancer with lower methylation of RASSF1A described for NSCLC and higher for SCLC (Table 2). In breast cancer, it was shown that RASSF1A has a higher methylation level in HER2 positive compared to HER2-negative breast tumors [120].

Interestingly, in acute myeloid leukemia, RASSF1A methylation occurs very rarely if ever (please see Table 1 in [127]) and RASSF1A expression is not affected [128] suggesting that RASSF1A is not involved in the pathogenesis. It will be interesting to determine why RASSF1A, which is methylated in such an extent in other tumors, remains intact in myeloid malignancy. It might be possible that other RASSFs such as RASSF6, 7 or 10 (please see Table 2) epigenetic silencing is responsible for leukemia’s development.

With the advantage of pyrosequencing we can now study promoter methylation with greater detail, gaining information about the degree of methylation of individual CpG sites. Pyrosequencing revealed high variability of a distribution and level of RASSF1A promoter methylation within and among pancreatic cancer samples [129]. The same variability was shown ten years earlier in breast cancer using an oligonucleotide-based microarray technique [130]. Based on the detailed data, Yan et al. concluded that RASSF1A promoter is characterized by progressive accumulation of methylation starting from the first exon to the promoter area of the RASS-F1A gene [130].

Besides cancer, epigenetic silencing of RASSF1A has been observed in ulcerative colitis (UC) patients [131], a form of inflammatory bowel disease (IBD). UC and Crohn’s disease (CD) are chronic intestinal idiopathic diseases characterized by inflammation of the GI tract resulting in abdominal pain, chronic diarrhea, and weight loss. Molecularly, inflammation is characterized by the hyperactivation of transcription factors such as NFκB and elevated production of cytokines to amplify the inflammatory response [132–134]. The activation of NFκB can originate from multiple surface receptors including Toll like receptors (TLR) or tumor necrosis factor α (TNFα) receptor (TNF-R1) that will ultimately result in cytokine production, such as IL-6 production. Interestingly, IL-6 can drive epigenetic loss of RASSF1A via DNA methyltransferase 1 (DNMT1) up-regulation [135,136] suggesting that inflammation can drive expression loss of RASSF1A and may explain why UC patients have epigenetic loss of RASSF1A. Importantly, IBD patients show an increased likelihood of developing colorectal cancer later in life and RASSF1A promoter methylation has been observed in colorectal cancers, suggesting that RASSF1A loss may be an early event in colorectal cancer development [131]. A similar epigenetic silencing of RASSF1A can be detected in 44% of pancreatic tissues patients [137] and it is known that inflammation of the pancreas is
promoting malignancy. Inflammation drives epigenetic silencing of the RASSF1A gene in a pre-cancer state (inflammation) may represent a molecular mechanism whereby chronic inflammation drives epigenetic silencing of the RASSF1A gene during a pre-cancer state. The 5′ CpG island of RASSF2 spans approximately 1.6 kb and RASSF2 has been shown to undergo epigenetic silencing in 88% of thyroid cancer patients, with 63% of these patients also showing RASSF5A epigenetic silencing. Epigenetic silencing was not observed in patients with goiter or follicular adenomas. In the same samples, RASSF3 and RASSF4 were not epigenetically silenced but RASSF5A was, suggesting selective roles for RASSF2 and 5A in the function of the thyroid gland. Furthermore, 5-aza-2′-deoxycytidine treatment was able to restore the expression of RASSF2 and 5A in a thyroid cancer cell line. RASSF2 methylation was also detected in colorectal cancer (CRC), gastric cancer and oral squamous cell carcinoma (please see Table 2 for the complete list and references). In squamous cervical cancer RASSF2 hypermethylation was associated with shorter survival time. Interestingly, in CRC patients the histone modification epigenetic mechanism was probably also involved in silencing of RASSF2, because treating cells with a histone deacetylase inhibitor augmented RASSF2 expression.

Promoter methylation of RASSF3 is rarely detected in cancer and was only described just recently in somatotroph adenoma.
(a subtype of pituitary adenoma) [69], however another recent study has shown that some polymorphisms can predispose to squamous cell carcinoma of the head and neck by modifying RASSF3 expression levels [147], providing another way of RASSF3 regulation.

Methylation of RASSF4 promoter in head and neck squamous cell carcinomas (HNSCC) was rather infrequent (13%, n = 54) [73] and a low methylation frequency (5%) was also reported for nasopharyngeal cancer [74]. However, a trend for higher RASSF4 methylation was detected in recurrent HNSCC. This correlates with a recent finding that RASSF4 expression was suppressed in a subpopulation of oral cancer stem-like cells/cancer-initiating cells [77], suggesting that RASSF4 plays a role in cell migration and invasive-ness control.

Early studies demonstrated loss of RASSF5A expression in lung tumor cell lines and primary lung tumors [7], Wilms’ tumor and renal cell carcinoma, colon cancer, as an apparent result of promoter specific hypermethylation (please see Table 2 for the complete list and references). Alternative to epigenetic silencing, RASSF4 may be downregulated through proteolysis catalyzed by calpain proteins, offering a means for tumor cells to flourish and escape growth inhibition [148]. RASSF4C promoter methylation is a rare event, possibly because its expression is limited to lymphoid tissue. Interestingly, it only has been detected in hepatocellular carcinoma and 8% of Merkel Cell Carcinoma (please see Table 2 for the complete list and references).

Similar to RASSF5, RASSF6 has been found to be epigenetically silenced in neuroblastoma [90] and childhood leukemia [91]. RASSF6 was found to be down-regulated by interactions with macrophages in vitro [149] to suggest that the immune system plays a role in regulation of RASSF6.

RASSF10 is another member of the RASSF family of proteins that is also epigenetically silenced. To date, 68% of malignant melanoma patient samples tested harbor epigenetically silenced RASSF10 [150]. In addition, RASSF10 promoter methylation has been observed in prostate cancer patients as well as up to 88% of pediatric leukemias, 50% of chronic lymphocytic leukemia, 66% of thyroid cancers, and 68% of melanoma (please see Table 2 for the complete list and references).

Not many reports exist currently on methylation of RASSF7 and 8 (see Table 2) and RASSF9 gene does not contain CpG island.

Although it is clear that epigenetics plays a crucial role in the regulation of expression of the RASSF proteins, the underlying mechanisms just started to emerge. It was shown recently that RASSF1A promoter methylation is regulated by p53 and death-associated protein 6 (DAXX) [151]. The authors have found that p53 binds to the RASSF1A promoter, recruits DAXX and DNMT1, leading to DNA methylation and subsequently to inactivation of RASSF1A. Interestingly, fluctuation in p53 protein levels did not affect the rates of RASSF1A methylation. Conversely, methylation of the RASSF1A promoter was critically controlled by DAXX, as the enforced overexpression of DAXX led to enhanced RASSF1A promoter methylation, whereas inhibition of DAXX reduced RASSF1A methylation [151].

To better understand the mechanism of RASSF1A epigenetic silencing, Palakurthy et al. performed a genome-wide RNAi screen and found that homeobox protein HOXB3 is required for RASSF1A promoter hypermethylation [152], a finding which was supported by a miRNA study later [153]. It appears that HOXB3 binds to the DMNT3B gene to increase its expression. DMNT3B then is recruited to the RASSF1A locus through interactions with polycomb repressor complex 2 (PRC2) and MYC, where it methylates the RASSF1A promoter [152].

Another player involved in epigenetic regulation of RASSF1A was reported recently [154]. Beckedorff et al. showed that non-spliced long non-coding RNA transcribed from the antisense strand of RASSF1A forms an RNA/DNA hybrid at the RASSF1A transcription site and recruits polycomb repressor complex 2 (PRC2) to the RASSF1A promoter. This results in increased methylation of histone H3K27 at the RASSF1A promoter and specific reduction of transcriptional activity. No DNA hypermethylation was detected in RASSF1A promoter in this study.

### 4. Other mechanisms of RASSFs regulation

In this section we will describe several other mechanisms of RASSF regulation with focus on microRNA and post-translational modifications of RASSF1A. Single nucleotide polymorphisms do exist for RASSF1A as another mechanism responsible for altering the biology of RASSF1A. This was recently reviewed in detail by Gordon et al. [155] and will not be discussed here.
4.1. microRNA regulation of RASSF1A

MicroRNAs (miRNAs) are short (~22 nucleotide) RNAs important for the regulation of numerous physiological processes. It appears that about 60% of human protein coding genes are regulated by miRNAs [156]. Many miRNAs are epigenetically regulated, associated with CpG islands and regulated by histone modifications. It is well established that miRNAs are often dysregulated in many types of cancer, and it has been proposed that miRNAs may function as either oncogenes or tumor suppressors depending on the target genes [157,158]. Currently 1872 human miRNAs are registered in the miRBase database [release 20, June 2013] with many miRNAs assigned to regulate specific genes [159].

Bioinformatic analysis (microrna.org) suggests that RASSF1A miRNA can be targeted by at least fifteen miRNAs (miR-326, -330, -149, -16, -497, -504, -410, -99a, -99b, -100, -124, -193, -193b, -182, -181a–d). However the only one so far experimentally validated is miR-602, which was not predicted. It has been shown recently that inhibition of mir-602 expression in hepatoma cells increased RASSF1A expression, promoted hepatoma cell apoptosis and inhibited cell proliferation suggesting that miR-602 had regulatory role in early stage of HBV-mediated hepatocarcinogenesis by inhibiting tumor suppressive functions of RASSF1A [160]. Since aberrant miR-602 expression was detected in early stages of hepatocarcinogenesis and correlated with RASSF1a protein loss the authors suggested that it may be a potential early marker for that condition (and possibly others) and may serve as a therapeutic target for HBV-positive hepatocellular carcinoma.

Persistent inflammation and increased IL-6 levels have been shown to up regulate DNMT activity to epigenetically silence genes such as RASSF1A. We can speculate that microRNA targeting DNMTs or other proteins involved in epigenetic regulation may also affect RASSF1A expression. One study revealed that overexpressed DNMT1 in colorectal cancer tissues and cell lines was associated with downregulated miR-342 [161]. Restoration of miR-342 resulted in a dramatic reduction of the expression of DNMT1 and in turn reactivated RASSF1A along with ADAM23, Hint1 and RECKS genes via promoter demethylation. Li et al. showed decreased DNMT3b association with RASSF1a promoter after mir-7 and mir-218 silencing of HOXB3 transcription factor in breast cancer cells [153]. Additionally, they detected increased histone acetylation at the RASSF1A promoter. It was demonstrated that miR-373 is able to regulate RASSF1A expression via MBD2 (Methyl-Cpg-Binding Domain Protein 2) in hilar cholangiocarcinoma. RASSF1A expression increased following suppression of MBD2 by miR-373 in QC8093 cells, and decreased after activation of MBD2 by anti-miR-373 inhibitor in HIBEPC cells [162]. Interestingly, in a parallel study the same group revealed that miR-373 gene promoter contained a CpG island and was regulated by methylation [163]. This phenomenon of miRNA-epigenetics regulatory networks was reviewed recently [164]. Therefore, these studies reveal an importance of microRNA regulation of RASSF1A. Theoretically the other RASSFs members can also be regulated by miRNAs, but currently there is no experimental proof of that in the scientific literature.

4.2. Post-translational modifications of RASSF1A

Post-translational modifications of RASSF1A are described as the regulatory mechanism that may affect the biological properties and stability of RASSF1A. RASSF1A is known to be phosphorylated at several serine and threonine residues under physiological conditions. Rong et al. reported that the mitotic kinase Aurora-A directly interacts with and phosphorylates RASSF1 (on Thr202/Ser203) during mitosis and this regulates the ability of RASSF1A to interact with microtubules and modulate cell cycle progression [165]. Recently, several other kinases, including ATM (ataxia telangiectasia mutated) [111], CDK4 (cyclin-dependent kinase-4) [166], PKC (protein kinase C) [167], MST1 [168], Aurora A [165], Aurora-B [169], and Chk1 [170] have also been shown to phosphorylate RASSF1A. Each of these kinases seems to regulate different aspects of RASSF1A function (see Table 3), suggesting that regulation of RASSF1A by phosphorylation is a complex process with multiple kinases involved that modulate RASSF1A function needed for various cellular processes.

As discussed above RASSF1A protein arrests cells in G1 phase and loss of RASSF1A leads to uncontrolled cell division in cancer. Since RASSF1A is expressed in normal cells, they have to have a mechanism to reduce RASSF1A and progress through cell cycle. It is well known that ubiquitination machinery plays a major role in regulation of factors important for cell cycle progression (see Fig. 2 in [171]). It appeared that ubiquitinylating enzyme complexes regulate RASSF1A as well. The Skp1-Cull1-F-box (SCF) ubiquitin ligase complex was the first complex discovered to regulate RASSF1A [166]. The Skp2 subunit of this complex interacts with RASSF1A and promotes its degradation at the G1-S transition of the cell cycle. Interestingly, RASSF1A has to be phosphorylated on Ser202 by cyclin D-cyclin-dependent kinase 4 to be able to interact with Skp2 [166]. In mitosis, Cullin 4A (CULL4A) promotes RASSF1A degradation [172]. In this case DNA damage-binding protein 1 directly interacts with RASSF1A and brings it to the CUL4A E3 ligase complex during mitosis. Ubiquitination therefore plays an important role in RASSF1A regulation and defects of ubiquitination machinery along with lower levels of RASSF1A expression were shown to be associated with hepatocellular carcinoma prognosis, and this may potentially serve as a diagnostic marker [173].

It was recently shown that the RASSF1A promoter has a p53 binding site 2718 bp upstream from the ATG transcription start codon, and that p53 is able to bind to the RASSF1A promoter and inhibit RASSF1A expression [174]. A transcription factor (TF) search revealed that almost all C-terminal RASSF genes (except RASSF4) have p53 and NFκB (except RASSF3 and 4) binding sites in their promoters (Table 4). At the same time, N-terminal RASSF genes have a distinct TF set, suggesting that not only is there structural differences between classical and N-terminal RASSFs [3], but they also might be transcriptionally regulated in different ways.

5. Conclusion

As described in this review, the tumor suppressor function of RASSF proteins are primarily determined by their ability to inhibit
cell growth and proliferation and to promote cell death in addition to other distinct functions. RASSF proteins exert diverse their functions through interaction with various proteins and are regulated through complex mechanisms, including promoter hypermethyla-

tion, histone modifications, protein post-translational modifications, polymorphic changes resulting in functional differences and miRNA regulation. Epigenetic silencing of RASSF genes via pro-
moter specific methylation is reported in many cancers and is be-
lieved to have a diagnostic and prognostic value. Recent data
suggest that inflammation may potentially serve as a trigger for 
epigenetic silencing which may contribute to cancer development. 

**Acknowledgments**

We would like to thank past and present members of the Baksh 
Research Group for their helpful discussions about RASSFs. We 
would also like to thank Adrienne DeCorby-Baksh for her helpful 
suggestions in the editing of this paper. All authors have read this 
paper and have accepted its submission. SB is supported by Grants 
from AI-HS, CIHR, WCHRI, CBCF and The Stollery Children’s Foun-
dation/Hair Massacre Grant (under the Department of Pediatrics) 
generously donated by the MacDonald family. MG is supported by 
Queen Elizabeth II Graduate Scholarship, Hair Massacre Graduate 
Studentship and Medical Sciences Graduate Program Scholarship 
Award. MS is supported by Queen Elizabeth II Graduate Scholar-
ship and Biochemistry Doctoral Research Scholarship.

**Appendix A. Supplementary data**

Supplementary data associated with this article can be found 
in the online version at http://dx.doi.org/10.1016/j.febslet.2014.02.041.

**References**

apoptotic Ras effector Nore1 may serve as a Ras-regulated tumor suppressor in the lung. J. Biol. Chem. 278, 21938–21943.
EAF4 as an interacting partner of the RASSF1A candidate tumor suppressor gene. Cancer Res. 64, 102–107.


Please cite this article in press as: Volodko, N., et al. RASSF tumor suppressor gene family: Biological functions and regulation. FEBS Lett. (2014), http://dx.doi.org/10.1016/j.febslet.2014.02.041


